Krystal Biotech’s (KRYS) Buy Rating Reiterated at Chardan Capital

Krystal Biotech (NASDAQ:KRYS)‘s stock had its “buy” rating reissued by Chardan Capital in a report issued on Wednesday,Benzinga reports. They currently have a $212.00 price objective on the stock. Chardan Capital’s price objective would indicate a potential upside of 25.08% from the stock’s previous close.

KRYS has been the topic of a number of other reports. Stifel Nicolaus raised their target price on Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a research note on Wednesday, September 11th. Citigroup increased their price target on Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. William Blair raised shares of Krystal Biotech to a “strong-buy” rating in a report on Friday, August 30th. HC Wainwright reissued a “buy” rating and set a $221.00 target price on shares of Krystal Biotech in a research note on Wednesday. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $206.67.

Krystal Biotech Price Performance

Shares of NASDAQ:KRYS traded up $0.45 during trading on Wednesday, reaching $169.49. 102,221 shares of the company’s stock traded hands, compared to its average volume of 321,637. The stock has a market capitalization of $4.87 billion, a P/E ratio of 95.76 and a beta of 0.80. Krystal Biotech has a 12 month low of $107.50 and a 12 month high of $219.34. The company has a 50 day moving average of $181.01 and a 200-day moving average of $185.37.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.84 by $0.07. The business had revenue of $83.84 million for the quarter, compared to analysts’ expectations of $82.94 million. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The business’s quarterly revenue was up 879.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.67) EPS. Equities research analysts predict that Krystal Biotech will post 2.97 earnings per share for the current fiscal year.

Insider Buying and Selling at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $164.78, for a total value of $4,119,500.00. Following the transaction, the insider now owns 1,475,882 shares of the company’s stock, valued at approximately $243,195,835.96. This trade represents a 1.67 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 14.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Summit Trail Advisors LLC purchased a new stake in shares of Krystal Biotech in the third quarter valued at $1,893,000. Swiss National Bank raised its position in Krystal Biotech by 8.0% during the third quarter. Swiss National Bank now owns 39,100 shares of the company’s stock valued at $7,117,000 after buying an additional 2,900 shares during the period. Sei Investments Co. lifted its stake in Krystal Biotech by 18.9% in the 2nd quarter. Sei Investments Co. now owns 40,115 shares of the company’s stock worth $7,367,000 after acquiring an additional 6,363 shares in the last quarter. Shaker Investments LLC OH acquired a new stake in Krystal Biotech during the 3rd quarter worth about $532,000. Finally, Citigroup Inc. grew its stake in Krystal Biotech by 65.4% during the 3rd quarter. Citigroup Inc. now owns 35,084 shares of the company’s stock valued at $6,386,000 after acquiring an additional 13,874 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).